- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01886352
Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA). (IPLA)
In this study, we will compare 3 treatments. The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) . The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery . The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic. We will use non-diluted 0.5% levobupivacaine delivered directly onto the target sites both at the beginning and the end of surgery. The drug will be delivered using OptiSpray® surgical spray device, an inexpensive delivery system that will direct a fine mist of drug directly to the areas of the peritoneal cavity that are theoretically the cause of post-op pain (diaphragms, peritoneal abdominal surface, surgical dissection site).
Our primary goal is to assess the efficacy of intraperitoneal atomization of levobupivacaine in reducing postoperative pain and of opioid requirements in patients undergoing gynecological laparoscopic procedures in one-day surgery.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- Ghent University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who are planned for gynaecological laparoscopic interventions on an ambulatory basis.
Exclusion Criteria:
- Less than 18 year old.
- Weight less than 50 kg and more than 80 kg.
- Pregnant.
- Prisoners;
- Allergic to topical anesthetics (Amides specifically).
- Allergic to Opioids as a class.
- Currently or within the last 30 days been prescribed an opiate medication.
- Chronic pain syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Infiltration of portal sites with 0,5% levobupivacaine.
The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
|
All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
|
Experimental: Additional injection of 0.5% levobupivacaine via a trocar
The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
|
All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar.
At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
|
Experimental: Additional intraperitoneal atomization of levobupivacaine.
The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
|
All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative pain intensity after laparoscopic gynaecological surgery in 1-day hospital setting.
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Pain evaluation will be done using an 11-point numeric rating scale (0 = no pain, 10 = worst pain possible).
|
Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Post-operative shoulder pain after laparoscopic gynecological procedure in 1-day hospital setting.
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Pain evaluation will be done using an 11-point numeric rating scale (0 = no pain, 10 = worst pain possible).
|
Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-operative opioid analgesic requirements after laparoscopic gynaecological surgery.
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Piritramide 0,05 mg/kg
|
Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Post-operative pain intensity after laparoscopic gynaecological surgery from hospital discharge until 24 hrs post-operatively.
Time Frame: Patients will be followed until 24 hours post-operatively.
|
Patients will be asked to evaluate their pain at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively using an 11-point numeric rating scale (0=no pain and 10= worse pain possible) and report it by telephone.
|
Patients will be followed until 24 hours post-operatively.
|
Post-operative shoulder pain after laparoscopic gynecological surgery from hospital discharge until 24 hrs post-operatively.
Time Frame: Patients will be followed until 24 hours post-operatively.
|
Patients will be asked to evaluate their pain at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively using an 11-point numeric rating scale (0=no pain and 10= worse pain possible) and report it by telephone.
|
Patients will be followed until 24 hours post-operatively.
|
Post-operative nausea and vomiting (PONV) in the first 24 hrs post-operatively, after laparoscopic gynecological surgery.
Time Frame: Patients will be followed until 24 hours post-operatively.
|
Nausea and vomiting will be evaluated every 15' during the first 2 hrs, every 30' until hospital discharge, using a PONV verbal descriptor scale 0 to 2 points : 0=no nausea, 1=any nausea, 2 =vomiting.
After discharge, patients wil be asked to evaluate PONV at 6 hrs, 12 hrs, 18 hrs and 24 hrs post-operatively and report it by telephone.
|
Patients will be followed until 24 hours post-operatively.
|
Post-operative sedation until hospital discharge, after laparoscopic gynecological surgery.
Time Frame: Patients will be followed up to 6 hrs post-operatively.
|
Sedation will be evaluated at 0, 1, 2, 4, 6 hrs post-operatively, using the Ramsay sedation score (1= anxious and agitated, 2= cooperative, tranquil, oriented, 3=responds only to verbal commands, 4= asleep with brisk response to light stimulation, 5=asleep without response to light stimulation, 6=non-responsive).
|
Patients will be followed up to 6 hrs post-operatively.
|
Time until discharge from recovery room.
Time Frame: Up until discharge from recovery room post-operatively, probably a few hours.
|
Discharge criterion: aldrete ≥ 9/10.
|
Up until discharge from recovery room post-operatively, probably a few hours.
|
Time until discharge from hospital.
Time Frame: Patients will be followed until an estimated 24 hours post-operatively.
|
Discharge criterion : modified aldrete ≥ 12/14.
|
Patients will be followed until an estimated 24 hours post-operatively.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc Coppens, MD, University Hospital, Ghent
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013/089
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain, Postoperative
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Ankara City Hospital BilkentRecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | SternotomyTurkey
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Aydin Adnan Menderes UniversityCompleted
-
Aydin Adnan Menderes UniversityCompletedAcute Postoperative Pain | Chronic Postoperative PainTurkey
-
Maimonides Medical CenterCompletedPOSTOPERATIVE PAINUnited States
-
University Hospital, AntwerpUnknown
-
VA Office of Research and DevelopmentRecruitingTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty (Postoperative Pain)United States
-
VA Office of Research and DevelopmentCompletedTotal Knee Arthroplasty (Postoperative Pain) | Total Hip Arthroplasty(Postoperative Pain)United States
Clinical Trials on Standard Injection of Levobupivacaine in portal sites.
-
The Methodist Hospital Research InstituteCollaborating for the Advancement of Interdisciplinary Research in Benign...RecruitingOveractive Bladder | Lower Urinary Tract Symptoms | Neurogenic Bladder | Neurogenic Detrusor Overactivity | Neuro: Neurogenic BladderUnited States
-
Istanbul UniversityRecruitingEndometrial Cancer | Sentinel Lymph NodeTurkey
-
Brainstorm-Cell TherapeuticsHadassah Medical OrganizationCompletedAmyotrophic Lateral SclerosisIsrael
-
University Hospital, GrenobleUniversity Hospital, MarseilleRecruitingLupus Erythematosus, SystemicFrance
-
Memorial Sloan Kettering Cancer CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditionsUnited States
-
University Hospital, GhentCompletedRupture of the Anterior Cruciate Ligament With Instability of the Knee JointBelgium
-
Guy's and St Thomas' NHS Foundation TrustRecruitingAnesthesia, Local | Thoracic Neoplasm | Acute Post-thoracotomy Pain | Chronic Pain Post-ProceduralUnited Kingdom
-
University of British ColumbiaPacific Centre for Reproductive MedicineTerminated
-
University Hospital, MontpellierUnknownHydrocele | Inguinal or Ovarian Hernia | Cord Kyst | Local Analgesia Block | One to Five YearsFrance